-
公开(公告)号：EP0787011B1
公开(公告)日：2008-10-22
申请号：EP95937005.7
申请日：1995-10-25
申请人： NOVARTIS AG , Novartis Pharma GmbH
IPC分类号： A61K31/436 , A61K9/107 , A61K9/48
CPC分类号： A61K9/0019 , A61K9/1075 , A61K9/4858 , A61K31/436 , A61K38/13 , A61K47/12
摘要： This invention provides a microemulsion pre-concentrate comprising a difficultly soluble active agent and a carrier medium comprising: 1) a hydrophilic phase which comprises dimethylisosorbide and/or a lower alkyl alkanoic ester, 2) a lipophilic phase, and 3) a surfactant. The active agent may be a cyclosporin or a macrolide. In another aspect, this invention provides a pharmaceutical composition for enteral or parenteral administration comprising a macrolide and an acid.
-
公开(公告)号：EP0988046B1
公开(公告)日：2004-09-15
申请号：EP98904156.1
申请日：1998-01-28
申请人： Novartis AG , Novartis Pharma GmbH
发明人： MEINZER, Armin , HAEBERLIN, Barbara
CPC分类号： A61K9/1075 , A61K9/4858 , A61K9/4866 , A61K38/13 , Y10S514/962
摘要： The present invention provides a hard gelatine capsule containing a pharmaceutical composition comprising cyclosporin A in a mixture with a surfactant of HLB value at least 10, substantially free of any oil and when a hydrophilic phase is present, the hydrophilic phase being a polyethylene glycol and/or a lower alkanol provided that any lower alkanol present is present in less than 12 % of the total weight of the composition absent the hard gelatine capsule.
-
公开(公告)号：EP1432408A1
公开(公告)日：2004-06-30
申请号：EP02774661.9
申请日：2002-09-27
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K9/20 , A61K31/435 , A61K31/445
CPC分类号： A61K9/0056 , A61K9/145 , A61K9/146 , A61K9/2009 , A61K9/2027 , A61K9/2077 , A61K31/435 , A61K31/445
摘要： A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
-
14.发明公开PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND OBSTRUCTIVE AIRWAYS DISEASES 审中-公开药物组合物炎性和阻塞性呼吸系统疾病的治疗
公开(公告)号：EP1965792A2
公开(公告)日：2008-09-10
申请号：EP06818678.2
申请日：2006-11-20
申请人： Novartis AG
CPC分类号： A61K31/4704 , A61K31/40 , A61K31/56 , A61K31/58 , A61K2300/00
摘要： A medicament comprising, separately or together (A) a compound of formula (I) in free or salt or solvate form, a glycopyrronium salt; and (Q a compound of formula (II) for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
-
公开(公告)号：EP1233757A2
公开(公告)日：2002-08-28
申请号：EP00993236.9
申请日：2000-11-28
申请人： Novartis AG
发明人： HAEBERLIN, Barbara
IPC分类号： A61K9/14 , A61K9/12 , A61K31/165
CPC分类号： A61K9/0075 , A61K9/4858 , A61K31/167 , A61K31/19 , A61K47/26 , Y10S514/826
摘要： The use of a dry powder comprising (A) formoterol, or a pharmaceutically acceptable salt or solvate thereof, or solvate of said salt, and (B) a pharmaceutically acceptable particulate diluent or carrier in an amount of from 400 νg to 5000 νg per νg of (A) for the preparation of an inhalable medicament for the treatment of chronic obstructive pulmonary disease.
-
16.发明公开PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TRANSPLANT REJECTION, AUTOIMMUNE OR INFLAMMATORY CONDITIONS COMPRISING CYCLOSPORIN A AND 40-0-(2-HYDROXIETHYL)-RAPAMYCIN 失效时锁定，在WIRKUND移植排斥复方制剂，自身免疫性疾病和炎症什么环孢素A联合国40-O-（2-羟乙基）雷帕霉素CONTAINS
公开(公告)号：EP0956034A1
公开(公告)日：1999-11-17
申请号：EP97937526.0
申请日：1997-07-29
申请人： Novartis AG
CPC分类号： A61K31/70 , A61K9/146 , A61K9/4858 , A61K31/445 , A61K31/45 , A61K38/13 , A61K45/06 , A61K2300/00
摘要： A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
-
公开(公告)号：EP0892640A2
公开(公告)日：1999-01-27
申请号：EP97919330.0
申请日：1997-04-10
申请人： Novartis AG
CPC分类号： A61K31/365 , A61K9/4891 , A61K38/13 , Y10S514/885 , Y10S514/96 , Y10S514/962 , Y10S514/968 , A61K2300/00
摘要： This invention provides a pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to release mycophenolate in the upper part of the intestinal tract.
-
公开(公告)号：EP1432408B8
公开(公告)日：2011-03-02
申请号：EP02774661.9
申请日：2002-09-27
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K9/20 , A61K31/435 , A61K31/445
CPC分类号： A61K9/0056 , A61K9/145 , A61K9/146 , A61K9/2009 , A61K9/2027 , A61K9/2077 , A61K31/435 , A61K31/445
摘要： A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
-
公开(公告)号：EP1432408B1
公开(公告)日：2010-10-27
申请号：EP02774661.9
申请日：2002-09-27
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K9/20 , A61K31/435 , A61K31/445
CPC分类号： A61K9/0056 , A61K9/145 , A61K9/146 , A61K9/2009 , A61K9/2027 , A61K9/2077 , A61K31/435 , A61K31/445
摘要： A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
-
20.发明公开
公开(公告)号：EP1957072A1
公开(公告)日：2008-08-20
申请号：EP06818673.3
申请日：2006-11-20
申请人： Novartis AG
IPC分类号： A61K31/4704 , A61K31/40 , A61K31/58 , A61P11/00 , A61P43/00
CPC分类号： A61K31/40 , A61K31/4704 , A61K31/58 , A61K2300/00
摘要： A medicament comprising, separately or together (A) a compound of formula (I) in free or salt or solvate form, wherein W, Rx, Ry, R1, R2, R3, R4, R5, R6 and R7 have the meanings as indicated in the specification; (B) a glycopyrronium salt; and (C) mometasone furoate; for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.013 秒)
